[go: up one dir, main page]

MX2016012915A - Profarmacos de inhibidores de la transcriptasa inversa del virus de la inmunodeficiencia humana (vih). - Google Patents

Profarmacos de inhibidores de la transcriptasa inversa del virus de la inmunodeficiencia humana (vih).

Info

Publication number
MX2016012915A
MX2016012915A MX2016012915A MX2016012915A MX2016012915A MX 2016012915 A MX2016012915 A MX 2016012915A MX 2016012915 A MX2016012915 A MX 2016012915A MX 2016012915 A MX2016012915 A MX 2016012915A MX 2016012915 A MX2016012915 A MX 2016012915A
Authority
MX
Mexico
Prior art keywords
reverse transcriptase
prodrugs
hiv reverse
transcriptase inhibitors
compounds
Prior art date
Application number
MX2016012915A
Other languages
English (en)
Inventor
Christopher S Burgey
Patel Mehul
BALSELLS Jaume
F Fritzen Jeffrey
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2016012915A publication Critical patent/MX2016012915A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen compuestos de fórmula I, (ver Fórmula]) en donde R1 y R2 se definen en la presente; los compuestos de fórmula I son útiles en la inhibición de la transcriptasa inversa del VIH, la profilaxis y el tratamiento de la infección por el VIH, y la profilaxis, la demora en el inicio o la progresión y el tratamiento del SIDA; los compuestos pueden usarse como ingredientes en composiciones farmacéuticas, opcionalmente en combinación con otros antivirales, inmunomoduladores, antibióticos o vacunas.
MX2016012915A 2014-04-01 2015-03-27 Profarmacos de inhibidores de la transcriptasa inversa del virus de la inmunodeficiencia humana (vih). MX2016012915A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461973689P 2014-04-01 2014-04-01
PCT/US2015/022868 WO2015153304A1 (en) 2014-04-01 2015-03-27 Prodrugs of hiv reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
MX2016012915A true MX2016012915A (es) 2016-12-07

Family

ID=54241131

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012915A MX2016012915A (es) 2014-04-01 2015-03-27 Profarmacos de inhibidores de la transcriptasa inversa del virus de la inmunodeficiencia humana (vih).

Country Status (21)

Country Link
US (1) US10004740B2 (es)
EP (2) EP3125894B1 (es)
JP (1) JP6342011B2 (es)
KR (1) KR102440843B1 (es)
CN (1) CN106456639B (es)
AU (1) AU2015241247B2 (es)
BR (1) BR112016022722B8 (es)
CA (1) CA2944187C (es)
CY (1) CY1123582T1 (es)
DK (1) DK3125894T3 (es)
ES (1) ES2828951T3 (es)
HR (1) HRP20201780T1 (es)
HU (1) HUE051848T2 (es)
LT (1) LT3125894T (es)
MX (1) MX2016012915A (es)
PL (1) PL3125894T3 (es)
PT (1) PT3125894T (es)
RS (1) RS61016B1 (es)
RU (1) RU2693622C2 (es)
SI (1) SI3125894T1 (es)
WO (1) WO2015153304A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
RS61016B1 (sr) 2014-04-01 2020-12-31 Merck Sharp & Dohme Prolekovi inhibitora hiv reverzne transkriptaze
CN106008362B (zh) * 2016-05-24 2018-08-10 杰达维（上海）医药科技发展有限公司 一种嘧啶衍生物的制备方法
EP3730494B1 (en) 2017-12-22 2023-11-08 Sumitomo Chemical Company, Limited Heterocyclic compound and harmful arthropod controlling agent containing same
EP3898595B1 (en) 2018-12-18 2024-05-01 Merck Sharp & Dohme LLC Pyrimidone derivatives as selective cytotoxic agents against hiv infected cells
BR112021016488A2 (pt) 2019-02-20 2021-10-26 Sumitomo Chemical Company, Limited Composto de éter e composição de controle de artrópode nocivo contendo o mesmo
CA3141143A1 (en) * 2019-05-22 2020-11-26 Merck Sharp & Dohme Corp. Pyridinone derivatives as selective cytotoxic agents against hiv infected cells
JP7618642B2 (ja) * 2019-07-16 2025-01-21 ブリストル－マイヤーズ スクイブ カンパニー インターロイキンの調節におけるプロドラッグ
TW202304919A (zh) 2021-03-31 2023-02-01 印度商皮埃企業有限公司 稠合雜環化合物及其作為害蟲控制劑之用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665720A (en) 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
IT1305313B1 (it) * 1998-07-17 2001-05-04 Colla Paolo 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
SE9904045D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
CL2004000192A1 (es) 2003-02-07 2005-03-18 Janssen Pharmaceutica Nv Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja.
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
MXPA05010081A (es) 2003-03-24 2005-11-23 Hoffmann La Roche Bencil-piridazinonas como inhibidores de transcriptasa inversa.
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
WO2005026148A1 (en) * 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7288942B2 (en) * 2003-10-02 2007-10-30 Naoyuki Sato Plasma potential measuring method and apparatus, and plasma potential measuring probe
BRPI0506786A (pt) 2004-01-12 2007-05-22 Gilead Sciences Inc compostos antivirais de fosfonato de pirimidila e processos de uso
CN1934092A (zh) * 2004-03-23 2007-03-21 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
AU2005235692B2 (en) 2004-04-23 2011-11-10 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
WO2006067587A2 (en) 2004-12-22 2006-06-29 Pfizer Limited Nonnucleoside inhibitors of hiv-1 reverse transcriptase
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
AU2006303368B2 (en) 2005-10-19 2011-05-26 F. Hoffmann-La Roche Ag Non-Nucleoside Reverse Transcriptase Inhibitors
RU2008119412A (ru) 2005-10-19 2009-11-27 Ф.Хоффманн-Ля Рош Аг (Ch) N-фенил-фенилацетамидные ненуклеозидные ингибиторы обратной транскриптазы
EA200970510A1 (ru) 2006-11-24 2009-12-30 Такеда Фармасьютикал Компани Лимитед Гетеромоноциклическое соединение и его применение
US7803940B2 (en) 2006-11-24 2010-09-28 Takeda Pharmaceutical Company Limited Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
US8404253B2 (en) 2006-12-28 2013-03-26 Newport Laboratories, Inc. Modified live (JMSO strain) Haemophilus parasuis vaccine
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
CA2705834A1 (en) 2007-11-20 2009-05-28 Merck Sharp & Dohme Corp. Pyridinone non-nucleoside reverse transcriptase inhibitors
WO2009088729A1 (en) * 2008-01-08 2009-07-16 Merck & Co., Inc. Process for preparing n-substituted hydroxypyrimidinone carboxamides
RS54017B1 (sr) * 2010-03-30 2015-10-30 Merck Canada Inc. Ne-nukleozidni inhibitori reverzne transkriptaze
EP2558093A4 (en) 2010-04-08 2013-10-02 Merck Sharp & Dohme PRODRUGS OF HIV INVERTER TRANSCRIPTASE INHIBITOR
JO3470B1 (ar) * 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
RS61016B1 (sr) 2014-04-01 2020-12-31 Merck Sharp & Dohme Prolekovi inhibitora hiv reverzne transkriptaze

Also Published As

Publication number Publication date
KR102440843B1 (ko) 2022-09-29
LT3125894T (lt) 2020-12-10
HRP20201780T1 (hr) 2021-06-25
EP3125894A1 (en) 2017-02-08
US20170173015A1 (en) 2017-06-22
PL3125894T3 (pl) 2021-02-08
SI3125894T1 (sl) 2020-12-31
CN106456639A (zh) 2017-02-22
BR112016022722B1 (pt) 2023-03-07
KR20160133000A (ko) 2016-11-21
US10004740B2 (en) 2018-06-26
JP2017512802A (ja) 2017-05-25
WO2015153304A1 (en) 2015-10-08
BR112016022722A2 (pt) 2017-10-31
RS61016B1 (sr) 2020-12-31
CA2944187A1 (en) 2015-10-08
CY1123582T1 (el) 2022-03-24
CA2944187C (en) 2018-06-19
HUE051848T2 (hu) 2021-03-29
RU2016142611A (ru) 2018-05-03
JP6342011B2 (ja) 2018-06-13
EP3125894B1 (en) 2020-09-09
EP3785714A1 (en) 2021-03-03
BR112016022722B8 (pt) 2023-11-21
ES2828951T3 (es) 2021-05-28
AU2015241247A1 (en) 2016-10-06
PT3125894T (pt) 2020-11-05
EP3125894A4 (en) 2017-12-13
CN106456639B (zh) 2019-05-10
AU2015241247B2 (en) 2017-09-14
RU2016142611A3 (es) 2018-12-26
DK3125894T3 (da) 2020-11-16
RU2693622C2 (ru) 2019-07-03

Similar Documents

Publication Publication Date Title
PH12018500292A1 (en) Antiviral beta-amino acid ester phosphodiame compounds
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
PH12015500764A1 (en) 5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors
MX388757B (es) Profármacos de éster alifático antivíricos de tenofovir.
MX2016012915A (es) Profarmacos de inhibidores de la transcriptasa inversa del virus de la inmunodeficiencia humana (vih).
NZ724343A (en) 4’-substituted nucleoside-derivatives as hiv reverse transcriptase inhibitors
SG184347A1 (en) Non-nucleoside reverse transcriptase inhibitors
NZ733174A (en) Quinazoline derivatives used to treat hiv
NZ733125A (en) Isoquinoline compounds for the treatment of hiv
WO2015017393A3 (en) Piperazine derivatives as hiv protease inhibitors

Legal Events

Date Code Title Description
FG Grant or registration